What Are the Different Types of Advanced Therapy Medicinal Products?

Four frosted cryogenic vials of amber, rose, and clear liquid in a steel lab rack as a gloved hand reaches toward one

Advanced therapy medicinal products (ATMPs) fall into four types under EU law: gene therapy medicinal products, somatic cell therapy medicinal products, tissue-engineered products, and combined ATMPs, which pair one of those with a medical device. Each type has its own definition, regulatory requirements, and development hurdles. Below, we answer the most common questions about how these categories work and what developers should expect.

How is a product classified as an ATMP in the EU?

A product is classified as an ATMP when it meets the definition of a gene therapy medicinal product, a somatic cell therapy medicinal product, or a tissue-engineered product under Regulation (EC) No 1394/2007. A fourth group, combined ATMPs, includes products that incorporate a medical device alongside a cellular or tissue component.

Classification depends on how the product is made and what it is intended to do. Gene therapy products contain recombinant nucleic acids used to regulate, repair, replace, add, or delete a genetic sequence. Cell therapy products contain cells or tissues that have been substantially manipulated or are used for a different essential function in the recipient. Tissue-engineered products contain engineered cells or tissues used to regenerate, repair, or replace human tissue.

Two details often decide the outcome. First, minimal manipulation (such as simple cutting, grinding, or freezing) generally keeps a product outside the ATMP scope. Second, a product with both a pharmacological, immunological, or metabolic mode of action and a structural role needs careful analysis. Early classification work is worth the effort, because it shapes everything that follows, from ATMP clinical trials to quality requirements.

What is the difference between gene therapy and cell therapy ATMPs?

Gene therapy ATMPs work by delivering genetic material into a patient’s cells to change gene expression, while cell therapy ATMPs work by administering living cells that act through their biological activity. The first changes the instructions inside cells, and the second supplies cells that perform a function.

Gene therapy medicinal products

These products use vectors, such as viral vectors or plasmids, or other delivery systems to carry therapeutic sequences. They can be administered directly to the patient (in vivo) or used to modify a patient’s cells outside the body (ex vivo). A therapy that modifies a patient’s own T cells with a gene, for example, is both a gene therapy and a cell-based product, and it is regulated as a gene therapy medicinal product. Vaccines against infectious diseases are excluded from this category.

Somatic cell therapy medicinal products

These products rely on cells that have been manipulated to change their biological characteristics, or on cells used for a purpose different from their original function. The key distinction in cell therapy manufacturing is autologous vs allogeneic cell therapy. Autologous products use the patient’s own cells, which supports a highly personalized medicine approach but creates logistical complexity. Allogeneic products use donor cells, which allow batch production but raise questions about donor screening and immune compatibility.

What makes a combined ATMP different from other ATMPs?

A combined ATMP is different because it integrates a medical device as an essential part of the product, alongside viable cells or tissues, or non-viable cells or tissues that act in a way that is not secondary to the device. This dual nature means both medicinal product and device requirements apply.

Typical examples include cells seeded onto a biodegradable scaffold, or cells embedded in a matrix that is implanted as a single unit. The device component must meet the relevant medical device requirements, and the cellular component must meet ATMP requirements. Developers therefore need to show how the two parts work together and how each is controlled.

This creates extra layers of evidence. Manufacturers must address device conformity, biocompatibility, and the interaction between the device and the biological component, all within one regulatory dossier. For a combined ATMP, the interface between medicinal product rules and device rules is often where questions arise, so planning that interface early saves time later.

Can the CAT help determine whether a product is an ATMP?

Yes. The Committee for Advanced Therapies (CAT), a committee within the European Medicines Agency (EMA), offers a free scientific recommendation procedure on ATMP classification. Developers submit their product data, and the CAT issues a recommendation on whether the product meets the ATMP definition.

The recommendation is not legally binding, but it carries real weight and helps align expectations with regulators. It is especially useful for borderline products, such as those involving substantially manipulated tissues, novel scaffolds, or unusual modes of action. A clear classification outcome informs the development plan, the data package, and the choice of regulatory route.

Practical tips for a strong request:

  • Describe the manufacturing process in enough detail to show the degree of manipulation
  • State the intended therapeutic, preventive, or diagnostic purpose clearly
  • Explain the mode of action and the role of each component
  • For combination products, describe how the device and biological parts interact

What regulatory pathway applies to each type of ATMP?

All ATMPs follow the centralized marketing authorization procedure through the EMA, where the CAT prepares a draft opinion that the Committee for Medicinal Products for Human Use (CHMP) adopts. The European Commission then grants the authorization. The route is the same for gene therapy, cell therapy, tissue-engineered, and combined ATMPs.

What differs is the content of the dossier and the surrounding requirements:

  • Gene therapy: Expect additional focus on vector characterization, genetic stability, and environmental risk assessment, including GMO considerations
  • Cell therapy: Donor eligibility, traceability, and potency are central, along with comparability between production batches
  • Tissue-engineered products: Evidence of the regenerative or repair function is needed alongside quality data
  • Combined ATMPs: The device component needs its own conformity evidence, which is integrated into the marketing authorization

Before approval, ATMP clinical development proceeds through clinical trial applications in each Member State. Developers can also use options such as scientific advice and the PRIME scheme for products addressing unmet medical needs. Some ATMPs may qualify for hospital exemption in limited circumstances, which is a national route for custom-made products and not a substitute for central authorization.

What challenges do ATMP developers commonly face?

ATMP development challenges typically cluster around manufacturing, quality control, and clinical design. These products are complex, often variable by nature, and made in small batches, so standard approaches from conventional drugs rarely transfer neatly.

The most common difficulties include:

  • Starting materials: Donor tissue, cell banks, and vectors vary, so ATMP starting materials need robust qualification, screening, and traceability
  • Potency assays: Showing that a living product has the intended biological effect is hard, and regulators expect assays that reflect the mode of action
  • Manufacturing scale-up: Moving from a lab process to ATMP manufacturing at commercial scale, or scaling out for autologous products, can introduce variability
  • Comparability: Process changes during development require evidence that the product remains equivalent, which is demanding for products with limited batch history
  • Quality control: Short shelf lives and small sample volumes limit the testing available for ATMP quality control
  • Trial design: Small patient populations make ATMP clinical trials difficult to power, so patient stratification and biomarker-driven approaches become important

Many ATMPs sit at the heart of precision medicine. Biomarkers, genomic markers, and companion diagnostics help identify patients most likely to respond, which supports biomarker-driven clinical trials and more targeted therapy. Planning the diagnostic strategy alongside the product avoids delays, particularly when a companion diagnostic must be developed and approved in parallel.

How Starodub helps with ATMP development

We guide developers through the full regulatory journey for advanced therapies, from the first classification question to submission and beyond. Our team brings deep experience in complex biologics, and we keep the process practical, with short reporting lines and a single point of contact backed by collective expertise.

Here is how we support ATMP projects:

  • Classification strategy, including preparation for CAT classification requests
  • Regulatory pathway planning for gene therapy, cell therapy, tissue-engineered, and combined ATMPs
  • CMC support covering starting materials, potency assays, comparability, and manufacturing scale-up, backed by our CMC expertise
  • Dossier preparation and regulatory support for biologicals, including clinical trial applications and marketing authorization submissions
  • Guidance on combined products where medicinal product and medical device rules meet

With over 400 completed projects for more than 300 clients, we know where ATMP programs tend to stall and how to keep them moving. If you are planning an ATMP and want a clear route to market, contact us and let’s talk through your next step.

Related Articles

This content was generated with the help of AI and it may contain mistakes

Patrick Vronen
Management team member - Senior RA Consultant
Patrick Vronen

Let's Connect

Talk to an expert